BenevolentAI Stock price

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam 07:47:30 2024-03-01 am EST 5-day change 1st Jan Change
0.78 EUR +4.00% Intraday chart for BenevolentAI +2.63% -27.78%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site

Financials

Sales 2023 * 23M 29.04M 26.87M Sales 2024 * 45.35M 57.26M 52.97M Capitalization 75.4M 95.2M 88.07M
Net income 2023 * -49M -61.87M -57.24M Net income 2024 * -6M -7.58M -7.01M EV / Sales 2023 * 0.36 x
Net cash position 2023 * 67.2M 84.86M 78.5M Net cash position 2024 * 59.79M 75.5M 69.85M EV / Sales 2024 * 0.34 x
P/E ratio 2023 *
-1.86 x
P/E ratio 2024 *
-17.7 x
Employees 260
Yield 2023 *
-
Yield 2024 *
-
Free-Float 52.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.35%
1 week-3.85%
1 month-3.85%
3 months+44.23%
6 months-27.88%
Current year-30.56%
More quotes
1 week
0.73
Extreme 0.73
0.77
1 month
0.68
Extreme 0.675
0.80
Current year
0.68
Extreme 0.675
1.41
1 year
0.48
Extreme 0.48
2.84
3 years
0.48
Extreme 0.48
10.00
5 years
0.48
Extreme 0.48
10.00
10 years
0.48
Extreme 0.48
10.00
More quotes
Managers TitleAgeSince
Founder 48 13-10-31
Director of Finance/CFO - 23-09-10
Chairman 67 22-04-21
Members of the board TitleAgeSince
Chairman 67 22-04-21
Director/Board Member 69 22-04-21
Director/Board Member 68 20-06-30
More insiders
Date Price Change Volume
24-03-01 0.78 +4.00% 5 254
24-02-29 0.75 +1.35% 25,894
24-02-28 0.74 -1.33% 2,486
24-02-27 0.75 0.00% 5,084
24-02-26 0.75 -1.32% 64,577

Real-time Euronext Amsterdam, February 29, 2024 at 11:15 am EST

More quotes
BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The BenevolentAI PlatformTM powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.6417 GBP
Average target price
2.139 GBP
Spread / Average Target
+233.32%
Consensus
  1. Stock
  2. Equities
  3. Stock BenevolentAI - Euronext Amsterdam
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW